BC Week In Review | Mar 30, 2018
Clinical News

Polyphor reports Phase Ib data for breast cancer candidate

Polyphor Ltd. (Allschwill, Switzerland) reported data from an open-label, dose-escalation Phase Ib trial in 54 women with previously treated HER2-negative, CXC chemokine receptor 4 (CXCR4; NPY3R)-positive metastatic breast cancer showing that IV balixafortide (POL6326) plus...
BC Innovations | Dec 4, 2014

Merck Encycles through Canada

The first disclosed grant under Merck & Co. Inc. 's Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin α4b7 inhibitors for inflammatory bowel disease....
BioCentury | Sep 17, 2012
Product Development

Excited about cycling

New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides. While it remains to be seen...
BC Innovations | Sep 4, 2008
Targets & Mechanisms

CXCR4 for CNS Infections

The purpose of the blood-brain barrier is to limit trafficking of leukocytes into the immune-privileged CNS. However, this becomes an undesirable trait when trying to clear acute CNS infections. 1 Indeed, one component of the...
BC Week In Review | Jul 14, 2008
Clinical News

POL6326: Phase I data

In a U.K. Phase I trial in 74 healthy volunteers, POL6326 was well tolerated. The compound also mobilized HSCs into the bloodstream. Polyphor Ltd. , Allschwil, Switzerland   Product: POL6326   Business: Cancer   Molecular target:...
Items per page:
1 - 5 of 5